Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Z2GF
|
||||
Former ID |
DIB003126
|
||||
Drug Name |
NI-101
|
||||
Synonyms |
BART; Ch12F6A; BIIB-037; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer!?s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer!?s disease), Neurimmune Therapeutics/Biogen Idec
|
||||
Drug Type |
Antibody
|
||||
Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 3 | [1], [2] | ||
Company |
Neurimmune Therapeutics AG
|
||||
Target and Pathway | |||||
Target(s) | Amyloid beta A4 protein | Target Info | [3] | ||
KEGG Pathway | Notch signaling pathway | ||||
Alzheimer's disease | |||||
Reactome | Nuclear signaling by ERBB4 | ||||
Degradation of the extracellular matrix | |||||
Regulated proteolysis of p75NTR | |||||
NRIF signals cell death from the nucleus | |||||
Activated NOTCH1 Transmits Signal to the Nucleus | |||||
Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
EPH-ephrin mediated repulsion of cells | |||||
WikiPathways | Notch Signaling Pathway | ||||
Signaling by ERBB4 | |||||
Signaling by NOTCH3 | |||||
Signaling by NOTCH4 | |||||
Signaling by NOTCH1 | |||||
Signaling by NOTCH2 | |||||
Notch Signaling Pathway | |||||
Alzheimers Disease | |||||
Signalling by NGF | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02484547) 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8325). | ||||
REF 3 | Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.